fixedcel
elisa
develop
use
swine
testicl
st
cell
infect
virul
miller
strain
transmiss
gastroenter
viru
tgev
purifi
biotinyl
monoclon
antibodi
bmab
five
bmab
specif
peplom
e
five
react
nucleocapsid
n
one
react
e
protein
miller
strain
tgev
protein
asepharos
purif
mab
yield
protein
concentr
rang
mg
per
ml
ascit
separ
pool
nmab
e
e
use
monitor
synthesi
tge
viral
antigen
st
cell
h
postinfect
variou
multipl
infect
moi
epitop
n
protein
appear
sooner
lower
moi
e
e
protein
fixedcel
elisa
also
use
examin
rel
bind
affin
tgev
mab
concentr
bmab
produc
halfmaxim
signal
rang
pgml
ggml
nmab
ggml
e
assay
use
determin
neutral
concentr
four
neutral
lagml
ggml
one
e
ggml
competit
assay
bmab
unlabel
competitor
indic
least
two
major
antigen
site
exist
antigen
site
present
nprotein
miller
tgev
transmiss
gastroenter
tge
contag
enter
viral
infect
swine
caus
highest
mortal
rate
seroneg
piglet
week
age
tge
virion
consist
three
major
protein
nucleocapsid
n
protein
kda
two
membranebound
glycoprotein
e
e
e
glycoprotein
mw
kda
e
peplom
protein
mw
kda
e
protein
elicit
neutral
antibodi
elucid
natur
epitop
tgev
monoclon
antibodi
mab
produc
number
attenu
strain
viru
laud
et
al
produc
mab
three
major
structur
protein
attenu
purdu
strain
tgev
panel
neutral
e
mab
test
nine
strain
tgev
viru
neutral
vn
cell
cultur
immunofluoresc
ccif
assay
sever
mab
exhibit
diminish
bind
neutral
strain
competit
radioimmunoassay
identifi
four
major
antigen
site
b
c
protein
major
neutral
determin
cluster
b
site
mab
use
probe
sever
strain
porcin
tgev
felin
felin
infecti
periton
coronavirus
strong
conserv
site
b
e
protein
found
virus
test
conserv
site
also
observ
anoth
independ
panel
neutral
e
mab
gener
attenu
purdu
tgev
six
epitop
identifi
panel
detect
attenu
virul
viral
isol
obtain
unit
state
japan
europ
within
last
year
mab
also
map
onto
four
b
c
antigen
site
peplom
protein
anoth
studi
garw
et
al
gener
neutral
mab
virul
british
fs
strain
tgev
react
sever
epitop
e
protein
relationship
among
antigen
site
identifi
e
protein
variou
investig
report
moreov
epitop
map
tgev
nprotein
describ
enzymelink
immunosorb
assay
elisa
detect
tge
viral
protein
antibodi
involv
use
partial
purifi
prepar
viru
competit
assay
map
viral
epitop
reli
partial
purifi
mab
radiolabel
laboratori
previous
report
gener
mab
e
n
viral
protein
virul
miller
strain
tgev
three
neutal
e
five
nonneutr
nmab
identifi
report
describ
fixedcel
elisa
use
three
addit
biotinyl
mab
detect
viral
epitop
applic
detect
appear
viral
epitop
follow
infect
cell
virul
tgev
monitor
viru
neutral
mab
map
epitop
tgev
protein
competit
assay
use
mab
gener
e
e
n
viral
protein
virul
miller
strain
c
pigpassag
tgev
use
produc
hybridoma
viru
partial
purifi
gut
content
infect
gnotobiot
pig
sucros
gradient
previous
describ
viru
use
infect
swine
testicl
st
cell
low
cell
culturepassag
miller
strain
tgev
virul
gnotobiot
pig
mab
c
tgev
gener
character
previous
describ
hybridoma
gener
fusion
spleen
cell
deriv
c
tgevimmun
mice
sp
myeloma
cell
presenc
polyethylen
glycol
hybridoma
test
posit
vn
ccif
test
expand
clone
three
time
growth
ascit
protein
specif
determin
radioimmunoprecipit
isotyp
mab
analyz
previous
describ
mab
n
protein
nmab
use
describ
previous
neutral
mab
protein
plu
nonneutr
e
f
neutral
e
e
also
use
characterist
mab
use
studi
summar
tabl
mab
purifi
x
cm
column
protein
asepharos
b
pharmacia
stockholm
sweden
equilibr
tb
mm
ph
contain
iggl
hsb
mm
ph
contain
modif
previous
describ
method
ascit
clarifi
centrifug
x
g
supernat
dilut
x
tb
appli
gel
room
temperatur
rt
column
wash
buffer
contain
vv
tween
tbst
immunoglobulin
ig
elut
sodium
acet
buffer
ph
collect
fraction
immedi
adjust
ph
tri
base
fraction
assay
protein
modif
method
sedmak
grosberg
fraction
contain
detect
protein
combin
purifi
mab
store
prepar
biotinyl
dialysi
overnight
volum
ph
biotinyl
reagent
enzotin
enzobiochem
new
york
ny
prepar
dissolv
hydroxysuccinimid
biotin
ester
dimethyl
sulfoxid
dmso
concentr
equal
protein
concentr
mgml
sampl
everi
ml
purifi
mab
gl
biotinyl
reagent
ad
allow
react
rt
reaction
biotinyl
mab
bmab
dialyz
tb
overnight
store
monolay
st
cell
grown
confluenc
tissu
cultur
plate
previous
describ
st
cell
infect
glwell
stock
tgev
pfuml
dilut
serumfre
minim
essenti
medium
mem
cell
incub
medium
remov
infect
uninfect
control
rins
twice
tb
cell
fix
min
aceton
air
dri
store
use
elisa
fix
cell
warm
rt
min
block
solut
nonfat
dri
milk
carnat
co
lo
angel
ca
tb
ad
well
h
block
solut
remov
gl
bmab
concentr
depend
purpos
assay
satur
level
individu
bmab
ad
well
allow
react
h
rt
overnight
rins
gl
dilut
horseradish
peroxidaseconjug
streptavidin
hrp
kirkegaard
perri
laboratori
inc
gaithersburg
md
tbst
ad
well
h
rt
hrp
remov
well
rins
time
tbst
chromogen
reagent
consist
mm
abt
bi
ethylenebenzthialin
sulfon
acid
dissolv
sodium
citrat
buffer
ph
ad
immedi
prior
assay
one
hundr
gl
abt
ad
well
allow
react
min
rt
reaction
termin
addit
gl
sd
absorb
sampl
monitor
nm
titertek
elisa
reader
flow
laboratori
inc
reston
va
absorb
control
expos
hrp
subtract
remain
sampl
valu
appear
e
e
n
epitop
inocul
st
cell
determin
threefold
sterial
dilut
inoculum
rang
neutral
tgev
e
e
perform
mix
threefold
serial
dilut
mab
equal
volum
tgev
mem
pfuml
dose
result
st
cell
contain
tge
viral
antigen
within
h
incub
determin
ccif
nonneutr
mab
use
control
mab
viru
mixtur
incub
l
h
prior
appli
st
cell
monolay
cell
incub
h
process
describ
fixedcel
elisa
viral
protein
detect
mixtur
npool
plu
e
describ
earlier
absorb
x
viru
fixedcel
elisa
control
incub
presenc
nonneutr
mab
f
unlabel
competitor
mab
serial
dilut
tbst
give
final
concentr
rang
tgml
gl
ad
fix
infect
mockinfect
st
cell
competit
studi
nmab
viru
stock
dilut
respect
satur
amount
bmab
determin
dose
respons
curv
bmab
dilut
twice
satur
concentr
usual
ggml
tbst
gl
ad
competitor
sever
concentr
rang
gg
ml
ggml
control
tl
tbst
e
control
e
use
competit
control
nmab
competit
mixtur
bmab
unlabel
competitor
incub
overnight
insur
equilibrium
plate
process
describ
standard
fixedcel
elisa
inhibit
calcul
differ
absorb
uncompet
bmab
bmabcompetitor
mixtur
divid
absorb
uncompet
bmab
strong
competit
consid
greater
inhibit
intermedi
competit
inhibit
weak
competit
less
igg
concentr
ascit
purifi
mab
rang
mgml
tabl
concentr
igg
ascit
fluid
pool
sever
sp
mice
mgml
indic
probabl
level
contamin
heterotog
antibodi
ascit
rang
gener
fixedcel
elisa
produc
absorb
valu
standard
deviat
rang
dose
respons
curv
bmab
present
fig
rel
affin
nmab
fig
h
rel
affin
fig
lb
concentr
bmab
give
halfmaxim
signal
determin
doserespons
curv
fig
summar
tabl
effect
e
iand
e
viru
neutral
summar
fig
tabl
tabl
ratio
rang
fig
n
epitop
appear
earlier
e
e
epitop
could
detect
much
lower
infect
inoculum
bmab
compet
unlabel
mab
variou
concentr
inhibit
curv
gener
similar
shown
two
repres
bmab
fig
competit
control
omit
clariti
result
competit
nand
e
summar
fig
b
competit
nmab
fig
reveal
two
three
cluster
epitop
antigen
site
one
n
identifi
e
anoth
n
compris
site
common
h
possibl
third
defin
may
situat
near
f
one
side
site
slightli
overlap
site
n
competit
e
fig
b
indic
mab
use
studi
bind
least
two
distinct
antigen
site
one
site
includ
epitop
recogn
c
h
degre
nonreciproc
bind
seen
h
versu
c
similar
situat
note
e
f
mab
two
mab
defin
second
site
e
compet
e
fixedcel
elisa
use
biotinyl
mab
appear
reliabl
system
detect
tge
viral
protein
number
advantag
system
biotinyl
mab
rapid
method
produc
label
antibodi
without
attach
rel
larg
enzym
moieti
might
significantli
alter
affin
specif
antibodi
simpler
safer
isotop
label
extens
timeconsum
purif
viru
requir
aspect
vivo
replic
viru
possibl
purifi
viral
prepar
examin
purif
mab
ascit
allow
us
determin
differ
concentr
mab
present
concentr
rang
suggest
caution
use
use
crude
ascit
fluid
experi
level
antibodi
may
signific
effect
interpret
result
fixedcel
elisa
allow
us
examin
appear
viru
epitop
vitro
infect
cell
fig
nucleocapsid
epitop
appear
earlier
accumul
somewhat
larger
quantiti
e
e
protein
result
interpret
repres
rel
level
protein
synthes
infect
cell
intact
virion
releas
cell
end
infect
appar
slower
rate
appear
e
e
epitop
may
reflect
longer
time
requir
protein
process
final
form
doserespons
curv
gener
techniqu
also
appear
use
determin
amount
infecti
viru
present
variou
prepar
correl
result
ccif
plaqu
viru
titrat
assay
data
shown
anoth
applic
fixedcel
elisa
detect
unneutr
viru
incub
tgev
neutral
mab
fig
sinc
purifi
unbiotinyl
mab
use
experi
neutral
curv
gener
may
give
accur
estim
neutral
obtain
use
unpurifi
ascit
fluid
tissu
cultur
supernat
hybridoma
neutral
titer
reflect
differ
concentr
immunoglobulin
rang
concentr
observ
fall
within
rang
concentr
ggml
laud
et
al
report
limit
neutral
concentr
e
purdu
attenu
strain
tgev
assum
doserespons
curv
fig
bmab
reflect
rel
affin
mab
ratio
amount
mab
produc
reduct
infect
viru
rel
affin
mab
maxim
signal
concentr
may
reflect
rel
effici
neutral
vnelisa
ratio
tabl
ie
greater
ratio
less
effect
neutral
mab
ratio
approxim
competit
studi
appear
antigen
site
wherea
ratio
nearli
time
greater
e
appear
share
antigen
site
nonneutr
mab
f
one
e
e
studi
differ
e
gener
attenu
mixtur
attenu
virul
strain
tgev
e
capabl
neutral
virul
tgev
absenc
complement
concentr
compar
sever
e
fig
mab
produc
laud
et
al
e
protein
attenu
purdu
strain
tgev
demonstr
low
viru
neutral
titer
less
ascit
examin
complementdepend
neutral
jimenez
et
al
use
anoth
set
mab
attenu
purdu
strain
tgev
report
low
neutral
viru
e
presenc
absenc
complement
wherea
sever
e
demonstr
dramat
sevento
eightfold
stimul
neutral
index
presenc
complement
effect
guinea
pig
rabbit
swine
complement
neutral
titer
mab
rais
mixtur
attenu
purdu
virul
miller
strain
tgev
examin
wood
et
al
mab
e
peplom
similar
vn
titer
presenc
absenc
complement
sourc
wherea
mab
e
protein
neutral
activ
presenc
complement
contrast
result
current
studi
may
due
part
fact
virul
miller
strain
use
immun
mous
infect
agent
viru
neutral
assay
use
competit
assay
determin
antigen
site
e
n
protein
reflect
also
import
consid
affin
interpret
result
chose
lower
limit
strong
competit
antigenlimit
assay
site
satur
mab
ratio
three
time
unlabel
competitor
one
would
expect
see
reduct
mab
ident
affin
cut
mere
attempt
defin
limit
degre
error
result
competit
e
defin
two
antigen
site
e
protein
howev
possibl
elimin
possibl
result
may
reflect
differ
site
upon
bind
mab
either
conform
chang
steric
block
two
group
observ
chang
bind
mab
tgev
e
protein
site
certain
mab
site
b
actual
enhanc
bind
mab
site
possibl
present
identifi
antigen
site
might
other
identifi
inform
may
avail
follow
exchang
mab
compar
competit
assay
result
nmab
competit
difficult
interpret
n
protein
kda
rel
small
contain
within
virion
tightli
selfassoci
within
cell
appear
brightli
fluoresc
aggreg
cytoplasm
infect
cell
ccif
assay
consequ
area
n
protein
avail
bind
may
provid
fewer
epitop
cluster
fewer
antigen
site
therefor
subject
steric
hindranc
report
describ
fixedcel
elisa
use
biotinyl
monoclon
antibodi
e
e
n
protein
tgev
provid
simpl
rapid
techniqu
detect
tgev
epitop
sever
applic
provid
use
inform
appear
viral
antigen
infect
titer
tgev
rel
affin
neutral
concentr
mab
use
competit
assay
identifi
epitop
tgev
viral
protein
fixedcel
elisa
bmab
may
use
techniqu
reagent
futur
studi
detect
diagnosi
tgev
infect
use
bmab
n
protein
tgev
may
especi
use
earli
rapid
detect
tgev
antigen
cell
cultur
inocul
fecal
specimen
tgev
suspect
pig
mucos
smear
pig
